Novartis India standalone net profit rises 161.40% in the September 2022 quarter

Novartis India standalone net profit rises 734.08% in the June 2022 quarter

Novartis India Standalone March 2022 Net Sales at Rs 98.32 crore, down 0.98% Y-o-Y

While the pharma industry welcomed the Union Budget, it also highlighted the critical need for government support in funding and creating the ecosystem for research. In an interview with CNBC-TV18's Anuradha Sengupta, Sanjay Murdeshwar, MD & Country President of Novartis India explains why government support for research is critical.



#CNBCTV18 #BusinessNews #ShareMarketToday #Nifty #Sensex

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

For latest news and updates visit our Website: https://bit.ly/2YbpXBM
Subscribe to our Channel: https://www.youtube.com/user/CNBCTV18
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

In Conversation With Sanjay Murdeshwar Of Novartis India | Exclusive Interview | CNBC TV18

Under the arrangement, Dr Reddy’s will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India.

Dr Reddy’s inks exclusive sales pact with Novartis India

Dr Reddy’s Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said

Dr Reddy’s Laboratories inks exclusive sales pact with Novartis India

Novartis India said its strategic business decision will lead to the separation of approximately 400 employees due to role redundancies.

Novartis India enters distribution pact with DRL for top brands, to lay off 400 employees

Novartis India, Dr Reddy’s enter pact to improve sales & distribution of medicines

Novartis India Standalone December 2021 Net Sales at Rs 98.96 crore, up 5.53% Y-o-Y

Novartis India CFO resigns

Tata Steel, Suryoday SFB, Sunteck Realty, Piramal Enterprises, Indiabulls Housing Finance, Somany Ceramics, Schneider Electric, RITES, Railtel, Prestige, Power Mech Projects, Novartis India, PNB Gilts, V2 retail, TCI Finance, NLC India, NHPC, NIACL, Mazda Ltd, HUDCO, HCC, and Goodyear are among comp…

Stocks to watch: Zomato, Yes Bank, Oil India

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods.